{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:38:31Z","timestamp":1765280311950,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009232","name":"Beatson Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C16583\/A28803"],"award-info":[{"award-number":["C16583\/A28803"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018703","name":"Cancer Research UK Beatson Institute","doi-asserted-by":"publisher","award":["C7932\/A25142"],"award-info":[{"award-number":["C7932\/A25142"]}],"id":[{"id":"10.13039\/501100018703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ctro.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:52:44Z","timestamp":1654948364000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Lynsey","family":"Devlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Grocutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiwot","family":"Chemu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Duffton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"McLoone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"O'Cathail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2022.06.003_b0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0010","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with Preoperative Radiotherapy in Rectal Cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2022.06.003_b0015","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3\u20134 Rectal Cancers: Results of FFCD 9203","volume":"24","author":"G\u00e9rard","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0020","doi-asserted-by":"crossref","unstructured":"Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. N Engl J Med. 1997;336:980\u20137. Doi: 10.1056\/NEJM199704033361402.","DOI":"10.1056\/NEJM199704033361402"},{"issue":"9","key":"10.1016\/j.ctro.2022.06.003_b0025","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2022.06.003_b0030","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101908","article-title":"Should we favour the use of 5 \u00d7 5 preoperative radiation in rectal cancer","volume":"81","author":"Kane","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctro.2022.06.003_b0040","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.30461","article-title":"Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States","volume":"123","author":"Mowery","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2022.06.003_b0045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.adro.2018.07.007","article-title":"Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States","volume":"3","author":"Abdel-Rahman","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial","volume":"18","author":"Erlandsson","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0060","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study","volume":"27","author":"Bujko","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12913-015-0845-9","article-title":"Direct costs of radiotherapy for rectal cancer: a microcosting study","volume":"15","author":"Hanly","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ctro.2022.06.003_b0070","doi-asserted-by":"crossref","first-page":"192249","DOI":"10.1001\/jamanetworkopen.2019.2249","article-title":"Cost-effectiveness of Short-Course Radiation Therapy vs Long-Course Chemoradiation for Locally Advanced Rectal Cancer","volume":"2","author":"Raldow","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctro.2022.06.003_b0075","article-title":"Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer","author":"Wang","year":"201914113","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0080","first-page":"209","article-title":"The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States","volume":"18","author":"Moore","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctro.2022.06.003_b0085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctro.2022.06.003_b0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2007.03.046","article-title":"Moderately Low Alpha\/Beta Ratio for Rectal Cancer May Best Explain the Outcome of Three Fractionation Schedules of Preoperative Radiotherapy","volume":"69","author":"Suwinski","year":"2007","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijrobp.2012.05.017","article-title":"Radiation Dose-Response Model for Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy","volume":"85","author":"Appelt","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.003_b0100","doi-asserted-by":"crossref","unstructured":"Couwenberg A , Burbach J , Berbee M, Lacle M, Arensman R, Raicu M, et al. (2020). Efficacy of dose-escalated chemoradiation on complete tumor response in patients with locally advanced rectal cancer (RECTAL-BOOST): a phase 2 randomized controlled trial. Int J Radiat Oncol Biol Phys. 2020;108(4):1008-1018. 10.1038\/s41571-021-00538-5.","DOI":"10.1016\/j.ijrobp.2020.06.013"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.003_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clon.2020.06.008","article-title":"Neoadjuvant radiotherapy dose escalation in locally advanced rectal cancer: A systematic review and meta-analysis of modern treatment approaches and outcomes","volume":"33","author":"Hearn","year":"2021","journal-title":"Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctro.2022.06.003_b0110","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41571-021-00538-5","article-title":"International consensus recommendations on key outcome measures for organ preservation after (chemo) radiotherapy in patients with rectal cancer","volume":"18","author":"Fokas","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0115","unstructured":"National rectal cancer intensity-modulated radiotherapy (IMRT) guidance. The Royal College of Radiologists.https:\/\/www.rcr.ac.uk\/publication\/national-rectal-cancer-intensity-modulated-radiotherapy-imrt-guidance (accessed August 13, 2021)."},{"key":"10.1016\/j.ctro.2022.06.003_b0120","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0167-8140(21)07325-4","article-title":"PH-0434 RTT verification of margin reduction strategy in rectal cancer short course radiotherapy","volume":"161","author":"Devlin","year":"2021","journal-title":"Radiother Oncol"},{"issue":"161","key":"10.1016\/j.ctro.2022.06.003_b0125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0167-8140(21)07004-3","article-title":"OC-0648 Dose escalation is feasible in short course radiotherapy of rectal cancer\u2013a planning study","volume":"2021","author":"Devlin","year":"2021","journal-title":"Radiother and Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic Normal Tissue Contouring Guidelines for Radiation Therapy: A Radiation Therapy Oncology Group Consensus Panel Atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.003_b0135","unstructured":"Stereotactic Ablative Body Radiotherapy (SBRT): A Resource. 2019. Available from: https:\/\/www.sabr.org.uk\/wp-content\/uploads\/2019\/04\/SABRconsortium-guidelines-2019-v6.1.0.pdf."},{"key":"10.1016\/j.ctro.2022.06.003_b0140","doi-asserted-by":"crossref","unstructured":"ICRU (2010) International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam intensity modulated radiotherapy (IMRT). ICRU Report 83, J. ICRU 10 (1), Oxford University Press, Oxford.","DOI":"10.1093\/jicru\/ndq002"},{"issue":"2","key":"10.1016\/j.ctro.2022.06.003_b0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90\u201305","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.003_b0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2006.10.021","article-title":"An analysis of 6-MV versus 18-MV photon energy plans for intensity-modulated radiation therapy (IMRT) of lung cancer","volume":"82","author":"Weiss","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0155","doi-asserted-by":"crossref","unstructured":"Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;93(4):757. https:\/\/dx.doi.org\/10.1016%2Fj.ijrobp.2015.07.2260.","DOI":"10.1016\/j.ijrobp.2015.07.2260"},{"issue":"4","key":"10.1016\/j.ctro.2022.06.003_b0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clon.2011.07.001","article-title":"Volumetric modulated arc therapy with simultaneous integrated boost for locally advanced rectal cancer","volume":"24","author":"Cilla","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0165","doi-asserted-by":"crossref","unstructured":"Bakkal BH, & Elmas O. Dosimetric comparison of organs at risk in 5 different radiotherapy plans in patients with preoperatively irradiated rectal cancer. Medicine. 2021;100(1). https:\/\/dx.doi.org\/10.1097%2FMD.0000000000024266.","DOI":"10.1097\/MD.0000000000024266"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.003_b0170","first-page":"1","article-title":"VMAT dosimetric study in rectal cancer patients","volume":"5","author":"Amaoui","year":"2020","journal-title":"Int Res J Med Biomed"},{"issue":"6","key":"10.1016\/j.ctro.2022.06.003_b0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1120\/jacmp.v17i6.6410","article-title":"A dosimetric evaluation of knowledge-based VMAT planning with simultaneous integrated boosting for rectal cancer patients","volume":"17","author":"Wu","year":"2016","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ctro.2022.06.003_b0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2021.09.002","article-title":"A novel approach for radiotherapy dose escalation in rectal cancer using online MR-guidance and rectal ultrasound gel filling\u2013Rationale and first in human","volume":"164","author":"Gani","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0185","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0167-8140(21)01811-9","article-title":"PO-1793: BioXmark liquid fiducials to enable radiotherapy tumor boosting in rectal cancer feasibility trial","volume":"152","author":"Berb\u00e9e","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.06.003_b0190","article-title":"Quantification of Organ Motion During Chemoradiotherapy of Rectal Cancer Using Cone-Beam Computed Tomography","author":"Chong","year":"20118142011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.06.003_b0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2019.05.001","article-title":"Systematic review and meta-analysis of small bowel dose\u2013volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy","volume":"138","author":"Holyoake","year":"2019","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.06.003_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1812-x","article-title":"Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy","volume":"15","author":"Dr\u00f6ge","year":"2015","journal-title":"BMC cancer"},{"key":"10.1016\/j.ctro.2022.06.003_b0205","unstructured":"Short-course Radiotherapy (5\u00d76Gy\/7Gy\/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer - https:\/\/clinicaltrials.gov\/show\/NCT03466424."},{"issue":"3","key":"10.1016\/j.ctro.2022.06.003_b0210","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025944","article-title":"Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ open"},{"key":"10.1016\/j.ctro.2022.06.003_b0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2020.09.033","article-title":"Radiotherapy Treatment plannINg study Guidelines (RATING): A framework for setting up and reporting on scientific treatment planning studies","volume":"153","author":"Hansen","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:26Z","timestamp":1762502966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630822000489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":43,"alternative-id":["S2405630822000489"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.06.003","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}